Relationship Broadens Scope to Key ASE and SPIL Facilities with Multi-Phase Deployment

Milestone Positions ASEH and Ainos as First-Mover in AI-Powered Scent Intelligence for the Semiconductor Industry

Earn Continuing Education credits and learn about the complex interplay between alcohol use disorder (AUD) and common co-occurring psychiatric conditions, including bipolar disorder, major depressive disorder, and generalized anxiety disorder.

New Cardiovascular Formula Lipidene Gains Attention for Natural Cholesterol and Artery Health Support, Backed by Botanical Science and Clinical Ingredient Data

How ProXental's essential oil and antioxidant dental gel supports gum appearance and oral freshness, with science-backed insights, ingredient analysis, daily usage plans, and long-term wellness integration strategies for 2025.

New Edition Offers Actionable Insights for MedTech Companies and More Targeting Hospital Infrastructure Growth in the Region

Strategic decision positions Jaguar to diversify treasury holdings with a long-term digital store of value

Webcast and conference call to be held on Monday, June 30th at 4:30 pm ET, dial in information below

Cardio Shield, developed by Apollo Research, emerges as the leading cardiovascular supplement of 2025 with a clinically inspired, natural formula designed to support blood pressure, circulation, and heart function - backed by real user results, scientific validation, and a 180-day risk-free guarantee.

Clinically Researched Supplement Targets Parathyroid Hormone to Support Balance, Ease Vertigo Symptoms, and Promote Inner Ear Health Naturally in 2025

A collection of articles, case reports and industry news for dental professionals.

Medical equipment provider delivers on-demand solutions for patients with high BMIs

Lon G. von Hurwitz, who will serve as chief strategist and senior advisor, brings 30-plus years of leadership experience in healthcare innovation, marketing, and public health initiatives and will guide efforts to bring the smart medication delivery technology to market in early 2026.

Canalevia^® (crofelemer delayed-release tablets), under the name Canalevia-CA1, is conditionally approved by the FDA for treatment of chemotherapy-induced diarrhea in dogs

Jaguar is exploring the possibility of approval of Canalevia for treatment of general diarrhea in dogs in the EU based on the statistically significant data from a completed study

Diarrhea is one of the most common reasons owners bring their dog to the veterinarian and the second most common reason for visits to the veterinary emergency hospital, yet there are currently no FDA-approved drugs to treat general diarrhea in dogs

Company strategy: In discussions with multiple potential animal health company partners to collaborate to bring Canalevia to regulatory approval and commercialization for general diarrhea globally

Medical Care Technologies' Infinite Auctions is Set to Reach for the Record Books with High End Memorabilia Sales.

The ‘Make America Healthy Again' initiative challenges pharmaceutical influence, promotes access to natural therapies, and proposes regulatory changes to FDA oversight, food safety, and vaccine review protocols.

Reverse Split Becomes Effective Friday, June 27, 2025

Shareholder- and Board-Approved Action Reduces Shares Outstanding to 1.4 million from 13.9 million, Expected to Ensure Continued Compliance with Nasdaq Listing Requirements

This report explores how DentaGuard's natural formulation-featuring clinically studied probiotics and plant-based compounds-supports microbiome balance, gum comfort, breath freshness, and daily oral care habits without relying on invasive procedures or synthetic additives.

Company's CEO, board members, other C-suite members, and institutional and accredited investors are participants in the extension of the bridge financing

Former PointClickCare and Current MacroHealth Chief Product Officer Deepens Company's Focus on Clinical Workflow Automation

Featured in MMR Magazine and Named a Top 100 Cosmetics Trend by TRENDHUNTER™

Enrollment Completed on Schedule; Topline Results Expected Mid Q3 2025

AI Nose and SLM SmellTech platform enter scale-up phase targeting robotics, automation, and environmental sensing markets

Kenmec and Ainos to show case AI Nose and SLM in Automation Taipei 2025 in August

~ Treatment to Evaluate Effect of Food on Overdose Protection of MPAR ~

~ Grant Funds from NIDA Accelerating Clinical Development Program ~

RevSpring, CarePayment, and Knowtion Health Recognized for Excellence in Patient Financial Technologies in Rankings Announced Today at HFMA ANI Conference

Rankings unveiled at HFMA Annual National Institute in Denver spotlight leading software solutions for Clearinghouse, Denial Management, and Claim Adjudication across hospitals and physician organizations

Comprehensive Rankings Highlight Leading Solutions Across Inpatient and Ambulatory Care Settings Based on Independent Client Satisfaction

Healthcare Finance Leaders Identify Top Software Solutions Across U.S. Hospital Segments Based on Real-World Results, ROI, and Financial Outcomes

As the HFMA ANI 2025 Meeting Kicks Off, New State Legislation Threatens to Reshape Revenue Cycle Management Disruption and Compliance Demands

Concierge Care Advisors Appoints Mary Cordova as Chief Concierge Officer and Promotes Shane Bray to Executive Vice President of Corporate Development

Enrollment in company's first-of-its-kind placebo-controlled Phase 2 study to evaluate the efficacy of crofelemer for microvillus inclusion disease (MVID) in pediatric patients has reached approximately 25%

Term loan maturity extended by 12 months to June 2029

Principal balance on term loan expanded to $13.0 million from $11.1 million currently

Expanded revolving line of credit facility by $1.5 million

Expanded facilities allow for added working capital flexibility as commercial launch of EXXUA is anticipated to occur in the fourth calendar quarter of 2025